Business · 31/05/2022Updated: 10/17/2026 · 1 min read
TG Therapeutics, Inc. Withdraws FDA Approval for UKONIQ Tablets
Summary
TG Therapeutics, Inc. has voluntarily requested the FDA to withdraw approval of its new drug application for UKONIQ (umbralisib tosylate) Tablets, equivalent to 200 milligrams Base, due to a voluntary request and waiver of a hearing.